Clinical Trial

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

Study acronym: PURIFY-TIMI 81
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-05
notable Trial sites expanded: 13 -> 28 locations 2026-07-15
Trial Details
NCT Number NCT07521007
Lead Sponsor Beijing Inno Medicine Co., Ltd.
Collaborators: The TIMI Study Group
Conditions Atherosclerosis, Coronary Artery Disease
Enrollment 456 participants
Start Date 2026-07-31
Primary Completion 2027-07-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-04